SCHEMBL2364060

SCHEMBL2364060

C=CCN(CC=C)CCC(=O)CO

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
KDM4E B2RXH2 8/20 0.38
KMT2A Q03164 4/20 0.38
MEN1 O00255 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.33
ATM Q13315 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2641260 0.86 ALDH1A1 (0.41) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL15234428 0.79 FAAH (0.46) ALDH1A1KMT2AMEN1TDP1TSHR
SCHEMBL2550180 0.77 KDM4E (0.43) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL7103835 0.77 ALDH1A1 (0.42) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL24444709 0.76 ALDH1A1 (0.40) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL9663210 0.76 ALDH1A1 (0.40) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL45568 0.73 ALDH1A1 (0.41) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL11662265 0.72 ALDH1A1 (0.42) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL1276123 0.72 KDM4E (0.44) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL13040556 0.71 ALDH1A1 (0.40) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605107-B2 Method of preparing a supported hydrotreating catalyst EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2009-10-20 US claimed
US-7538066-B2 Method of preparing a hydrotreating catalyst on a support containing a rare earth metal EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2009-05-26 US claimed
US-20070082811-A1 Method of preparing a hydrotreating catalyst on a support containing a rare earth metal EXXONMOBIL RESEARCH AND ENGINEERING COMPANY 2007-04-12 US claimed
US-20070072765-A1 Method of preparing a supported hydrotreating catalyst EXXONMOBIL RESEARCH AND ENGINEERING COMPANY 2007-03-29 US claimed
US-9035107-B2 Dehydrogenation process EXXONMOBIL CHEMICAL PATENTS INC. (US) 2015-05-19 US disclosed
US-9024078-B2 Dehydrogenation process EXXONMOBIL CHEMICAL PATENTS INC. (US) 2015-05-05 US disclosed
US-8969639-B2 Dehydrogenation process EXXONMOBIL CHEMICAL PATENTS INC. (US) 2015-03-03 US disclosed
US-8884075-B2 Process for producing phenol EXXONMOBIL CHEMICAL PATENTS INC. (US) 2014-11-11 US disclosed
US-20140148620-A1 Process for Producing Phenol EXXONMOBIL CHEMICAL PATENTS INC. (US) 2014-05-29 US disclosed
US-20120323046-A1 Dehydrogenation Process EXXONMOBIL CHEMICAL PATENTS INC. 2012-12-20 US disclosed
EP-2531480-A1 DEHYDROGENATION PROCESS ExxonMobil Chemical Patents Inc. (US) 2012-12-12 EP disclosed
US-20120302798-A1 Dehydrogenation Process EXXONMOBIL CHEMICAL PATENTS INC. 2012-11-29 US disclosed
US-20120271077-A1 Dehydrogenation Process EXXONMOBILE CHEMICAL PATENTS INC. (US) 2012-10-25 US disclosed
WO-2012050665-A1 PROCESS FOR PRODUCING PHENOL EXXONMOBIL CHEMICAL PATENTS INC. (US) 2012-04-19 WO disclosed
WO-2011096992-A1 DEHYDROGENATION PROCESS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-08-11 WO disclosed
WO-2011096994-A1 DEHYDROGENATION PROCESS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-08-11 WO disclosed
WO-2011096997-A1 DEHYDROGENATION PROCESS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148620-A1 Process for Producing Phenol HPD, CYP2J2, CYP2E1 ALDH1A1 1756/4885KDM4E 1303/4885KMT2A 3345/4885
US-20120271077-A1 Dehydrogenation Process ADH5, ADH1A, ADH1C ALDH1A1 40/4885KDM4E 2118/4885KMT2A 2800/4885
US-20120302798-A1 Dehydrogenation Process NDUFV1, NDUFV2, MAFG ALDH1A1 274/4885KDM4E 537/4885KMT2A 582/4885
US-20120323046-A1 Dehydrogenation Process ADH1A, ADH5, ADH1C ALDH1A1 85/4885KDM4E 3168/4885KMT2A 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.